Introduction with angiotensin converting enzyme-inhibitors with or without a diuretic has been demonstrated under
Of the 20 million people worldwide who suffer a stroke randomized double blind conditions of the PROGRESS each year, about half either die or are disabled.
[1,2] Surveys study, it is unclear whether the benefit is reflected in primary suggest that the prevalence of stroke in India is about care practice and in populations with different demographic 0.5%, with an annual mortality of over 1,00,000, that and clinical characteristics. Aim: To assess the effect and represents 1.2% of all deaths.
[3]
acceptability of perindopril with or without indapamide advances in the understanding and treatment of stroke, prevention of recurrent stroke, as reflected by its incidence.
prevention remains the strategy of paramount Setting and Design: Multicentre, prospective, observational importance. [4] study in the setting of primary care throughout India.
Effective control of hypertension has the potential to In spite of enormous of 3.3% (95% CI, 1.0-5.6). Conclusions: The incidence of recurrent stroke is similar to that observed under double blind randomized conditions in the treatment arm of the PROGRESS study. This suggests that perindopril ± indapamide-based prevention may be effective in reducing risk of recurrent stroke, (although the uncontrolled study design does not actually demonstrate this), in the setting of day-to-day clinical practice and among patients with different demographic and clinical characteristics than the PROGRESS population.
Key words: Cerebrovascular accident, perindopril, recurrent stroke for only a small proportion of patients. Angiotensin converting enzyme inhibitor (ACEI) and diuretic based prevention of recurrent stroke was demonstrated in the PROGRESS study [10] and is recommended by international guidelines.
[5] In comparison to placebo, the ACEI perindopril (4.0 mg/day) with or without indapamide (2.0-2.5 mg/day) reduced the risk of recurrent stroke by 28%. The benefit was in addition to the protection provided by other antihypertensive agents and antiplatelet therapy.
This suggests the possibility of effectively using ACEI ± indapamide-based treatment for prevention of recurrent stroke in day-to-day practice. However, there is no evidence that the risk reduction observed in the PROGRESS population under double blind randomized study conditions can be replicated in the primary care setting, especially in communities with different demographic and clinical characteristics. The objective of this study was to assess the effect and acceptability of perindopril ± indapamide based prevention of recurrent stroke, as reflected by its incidence, in the primary care setting of India. In a prospective, non-comparative, open label study of *± value are means plus/minus standard deviation. All other values are numbers of patients with the percentages of the group in parenthesis; TIA = Transient 12 months duration during 2003-2004, participating ischaemic attack; CAD = coronary artery disease physicians identified consecutive outpatients with a history of stroke (2 weeks after but within 5 years of the stable angina according to the patient's medical record. event) or TIA who were clinically stable for at least a After baseline assessment, patients received the open fortnight and who were not receiving an ACEI, label study medication and were followed up after 14, angiotensin receptor blocker or diuretic. Of these, patients 90, 180, 270, and 365 days. For the first 14 days without a specific indication or contraindication to an perindopril (COVERSYL, Serdia, India) was prescribed ACEI and diuretic or intolerance to these agents were at a dose of 2 mg per day. At subsequent follow ups, selected. Stroke was defined as evidence of an acute depending on blood pressure response and clinical disturbance of focal neurological function with symptoms judgment, physicians could adjust the study medication lasting more than 24 hours and thought to be due to intra-between perindopril 2, 4 mg or a fixed dose combination cerebral hemorrhage or ischaemia. TIA was defined as of perindopril 4 mg and indapamide 1.5 mg (COVERSYL evidence of an acute disturbance of focal neurological or PLUS, Serdia, India). These study medications were taken monocular function with symptoms lasting less than 24 once a day in the morning in addition to background hours and thought to be due to arterioembolic or medication for associated disease or other treatments for thrombotic vascular disease. Stroke was classified as the secondary prevention of stroke. Patients purchased ischaemic or hemorrhagic, on the evidence of either all drugs from the market on prescription. computed tomography or magnetic resonance imaging scan At each follow up, patients were examined for the After giving their written informed consent, patients were assessed at baseline for demographic, clinical and treatment, characteristics shown in Table 1 . Sphygmomanometric blood pressure measurements were made under standard conditions [5] and hypertension was defined as a previous record of at least two blood pressure readings above 140/90 mmHg or the regular intake of antihypertensive drugs. Previous fasting plasma glucose greater than 126 mg/dL or the requirement of hypoglycemic drugs was used to diagnose diabetes. Hypercholesterolemia was identified as previous total plasma cholesterol of above 7.0 mmol/L or treatment with statins. Atrial fibrillation was recognized by positive history or ECG evidence. Coronary artery disease was diagnosed by previous known myocardial infarction or occurrence of acute cerebrovascular events, blood pressure level, compliance with study medication and side effects. Recurrent stroke or TIA was defined and classified as at baseline. The proportion of tablets ingested out of those prescribed, was used to assess compliance with medication. Side effects were evaluated by asking openended questions. The measurement of serum creatinine was repeated at the end of the study.
Materials and Methods

Statistical analysis
Data was analyzed on an intention to treat basis. The primary outcome variable was the annual incidence of non-fatal and fatal stroke. The Kaplan-Meier procedure was used to estimate the cumulative combined hazard of ischaemic stroke, hemorrhagic stroke, and TIA. Continuous variables were expressed as means with their standard deviation and categorical variables as percentages with related 95% confidence intervals (CI).
Results
The 39 investigators recruited 298 outpatients with a stable stroke or TIA occurring between 2 weeks and 5 years after the event. The characteristics of these patients at baseline are summarized in Table 1 . Most patients were males in their sixth decade, with an ischaemic stroke of 6 months duration. In about one in ten the cerebrovascular . m e d k n o w event was a hemorrhagic stroke or TIA. A majority of patients had mild to moderate hypertension, but about one in four were either not previously diagnosed or were not receiving antihypertensive treatment. One in four patients were normotensive. Nearly all patients were receiving antiplatelet agents or statins, which provide protection against the risk of recurrent stroke.
Patients were under observation for a mean duration of 327.1 (SD, 119.3) days. By the end of planned follow up (12 months), 47 (15.8%) were lost to follow up, 15 (5.1%) withdrew, of which 13 were due to causes unrelated to the study treatments. There were five (1.7%) deaths during the study (1, due to cardiovascular; 3, due to other; and 1 of indeterminate cause). At the end of study, the number (%) of patients receiving the once daily study medications were 125 (41.9), perindopril 4 mg; 84 (28.2) fixed dose combination of perindopril and indapamide; and 22 (7.4) perindopril 2 mg. Mean compliance (% of tablets ingested out of those prescribed) with study medications ranged from 98.1% at day 14 to 99.6% at the end of the study.
Overall, the mean decrease in systolic (95% CI) / diastolic (95% CI) blood pressure from baseline with perindopril ± indapamide based treatment was 22.7 (19.8 to 25.6)/ 13.3 (11.7-14.9 ) mmHg. The mean reduction in systolic/ diastolic blood pressure in hypertensive patients was 27.9 (24.7-31.1)/16.0 (14.4-17.6 ) mmHg and in normotensive patients, 2.4 (0-5.7)/2.85 (0. 4-5. 3) mmHg [ Figure 1 ]. This decrease was maintained throughout the follow up, with a reported side effect in one patient. Other side effects were infrequent. One patient each complained of abdominal discomfort, nausea, feeling of weakness and giddiness. During the 12 months of perindopril ± indapamide based treatment, the number (annual incidence %) of recurrent cerebrovascular events were, ischaemic strokes 6 (2.0); hemorrhagic strokes, 2 (0.7); all strokes, 8 (2.7); TIA, 6 (2.0); and all strokes plus TIA 14 (4.7). There were no fatalities because of stroke. One patient developed stable angina and another suffered a myocardial infarction.
Discussion
The Kaplan-Meier estimate of cumulative recurrent stroke or TIA hazard [ Figure 2 ] at the end of one year's preventive treatment with the perindopril ± indapamide based regimen was 3.3% (95% CI, 1.0-5.6).
Of the 16 (5.4%) patients who reported side effects attributable to the study medication, two (0.7%) withdrew from the study due to cough and 11 (3.7%) patients complained of it at the first follow up after 14 days. At the end of 12 months treatment cough was Patients with a previous stroke that was clinically stable or with a history of TIA, received a flexible blood pressure lowering regimen with perindopril alone or in combination with indapamide for 12 months. The treatment reduced blood pressure in hypertensive patients, with little effect on those who were normotensive. The annual recurrent stroke incidence while on perindopril ± indapamide-based preventive treatment was 2.7% among patients at different stages of post stroke evolution (2 weeks to 54 months after their previous stroke or TIA) and against the background of other secondary preventive measures such as non-study antihypertensive drugs, antiplatelet agents, and statins. The treatment was acceptable to patients over the long term, with few side effects, a low frequency of cough and nearly complete compliance with the once daily dosage. Under the randomized double blind conditions of the PROGRESS study the annual recurrent stroke incidence in patients with a previous stroke or TIA assigned to the treatment arm was 2.7%.
[10] This study used similar recruitment criteria and active drug treatments as PROGRESS. However, our patients were about 6 years younger. Another major difference was a nearly 30% greater frequency of hypertension, that was about 10 mmHg higher at baseline in comparison to patients recruited in PROGRESS. Perhaps this difference in baseline blood pressure partly explains the large perindopril ± indapamide based prevention effectively reduces the risk of recurrent stroke in the setting of day to day clinical practice and among younger patients with higher levels of blood pressure. However, these results need to be confirmed in controlled studies of longer duration on a larger number of patients.
